What is the VA rating for Female Reproductive Organ Conditions and Disorders of the Breast?

38 CFR 4.116's Note 2 applies across the ENTIRE section -- not to one diagnostic code -- and directs that any claim involving loss or loss of use of one or more creative organs, or anatomical loss of one or both breasts, be separately reviewed under 38 CFR 3.350 for special monthly compensation (SMC) eligibility.

• This is confirmed, via fresh verbatim fetch cross-checked against two independent primary sources, as a distinct compensation mechanic OUTSIDE the ordinary 0-100 percent rating schedule -- SMC is not a percentage tier this hub computes.
• The Note's own implementing footnote appears specifically on DC 7617, 7618, 7619, 7620, 7626, and 7632 -- not on DC 7610-7615, the shared General Rating Formula codes.
• RatingScope discloses that SMC review may apply; it does not determine SMC eligibility itself. Review 38 CFR 3.350 separately, or with an accredited representative, for that determination.

Records to review: Records documenting organ removal, organ loss of use, or anatomical breast loss.

38 CFR 4.116's own title is 'Gynecological Conditions and Disorders of the Breast' -- one section covering both. VA simply examines the two areas using two separate forms (a Gynecological Conditions DBQ and a Breast Conditions and Disorders DBQ) for this one CFR section.

• This was confirmed during this hub's research phase specifically because the reviewer's own first-draft summary mischaracterized breast conditions as separate territory researched elsewhere -- caught and corrected before anything was logged, by re-quoting the section's own title and code list directly.
• DC 7626 (breast surgery), DC 7630 (malignant neoplasms of the breast), and DC 7631 (benign neoplasms and other injuries of the breast) are independently tracked codes within this section, alongside the gynecological-organ codes -- not merged or confused with each other.

Records to review: Breast Conditions and Disorders DBQ; Gynecological Conditions DBQ.

Six diagnostic codes (vulva/clitoris, vagina, cervix, uterus, fallopian tube, ovary) share one textually identical 3-tier formula: 30 percent (not controlled by continuous treatment), 10 percent (requires continuous treatment), 0 percent (does not require continuous treatment).

• The body part affected determines which diagnostic code is cited, not the percentage -- the tiers themselves are identical across all six codes.
• This shared-formula pattern mirrors the Thyroid and Parathyroid hub's approach to textually identical codes -- one function reused via label dispatch, never duplicated six times.

Records to review: Gynecological Conditions DBQ; Treatment records documenting whether symptoms are controlled.

Complete removal of the uterus and both ovaries (DC 7617), the uterus alone (DC 7618), or one or both ovaries (DC 7619) each carry a temporary 100 percent rating for the three months following surgery, then drop to a real permanent tier.

• Unlike several Thyroid and Parathyroid codes' unnamed post-window dispatch, each of these three codes' permanent tier is a genuine, named percentage: 50 percent (DC 7617), 30 percent (DC 7618), and 30 percent (both ovaries) or 0 percent (one ovary, DC 7619).
• The temporary 100 percent window applies for three months from the surgery date regardless of which of the three codes ultimately applies -- only the permanent tier that follows differs by code.

Records to review: Surgical records establishing the removal date and extent.

Pelvic organ prolapse (DC 7621) is a flat 10 percent, but its own text separately directs evaluating any genitourinary, digestive, or skin symptoms under their own diagnostic code(s) and combining those evaluations with this 10 percent rating.

• Confirmed via fresh verbatim fetch: the exact phrase directs to 'evaluate separately any genitourinary, digestive, or skin symptoms under the appropriate diagnostic code(s) and combine all evaluations with the 10 percent evaluation under DC 7621.'
• RatingScope discloses this combination requirement but does not auto-combine across hubs -- review any genitourinary, digestive, or skin symptoms under their own diagnostic code(s) separately.

Records to review: Records documenting any associated genitourinary, digestive, or skin symptoms.

Benign neoplasms of the gynecological system (DC 7628) and of the breast (DC 7631) both carry NO independent rating percentage, and both name the same base functional categories -- but DC 7631 adds breast-specific examples and a named destination code that DC 7628 does not.

• DC 7628's full text: 'Rate chronic residuals to include scars, lymphedema, disfigurement, and/or other impairment of function under the appropriate diagnostic code(s) within the appropriate body system' -- confirmed via two independent primary sources.
• DC 7631's own text: 'Rate chronic residuals according to impairment of function due to scars, lymphedema, or disfigurement (e.g., limitation of arm, shoulder, and wrist motion, or loss of grip strength, or loss of sensation, or residuals from harvesting of muscles for reconstructive purposes), and/or under diagnostic code 7626.'
• The real distinction is not category presence -- both name scars, lymphedema, disfigurement, and/or other impairment of function -- but that DC 7631 adds breast-specific illustrative examples and names a specific destination code (DC 7626, this same hub's own breast-surgery code), while DC 7628's destination remains generic.
• An earlier draft of this hub used an ellipsis when quoting DC 7628 ('rate chronic residuals ... under the appropriate diagnostic code(s)') that elided the shared category language, making the two codes look more different than they are -- corrected here to the full text.

Records to review: Gynecological Conditions DBQ or Breast Conditions and Disorders DBQ; Pathology records confirming benign status; Records documenting scars, lymphedema, disfigurement, or arm/shoulder/wrist functional impairment, if DC 7631 applies.

38 CFR 4.116's Note 1 still affirms that chronic residuals of surgical complications of pregnancy are ratable -- but DC 7623, the only diagnostic code that ever covered this subject, was removed from the schedule in 2018.

• Confirmed absent from two independent primary sources during this hub's research (RSCH-048's ND-1) -- a genuine zero-code gap in the current regulation, not an omission in this hub's own scope.
• There is no selectable diagnosis path for this in RatingScope's intake, since no diagnostic code currently exists to route to.

Records to review: Records documenting chronic residuals of surgical complications of pregnancy, if applicable.

DC 7624 (rectovaginal fistula, a 0-100 percent ladder based on leakage frequency) and DC 7625 (urethrovaginal fistula, a 0-100 percent ladder based on absorbent-material-change frequency) currently exist in force within this hub's DC 7610-7632 range, but their own tier content has not yet been authored here.

• Confirmed both codes currently exist in the live regulation via two independent primary sources -- this is an authored-scope gap, distinct from DC 7623's genuine regulation-removal gap.
• There is no selectable diagnosis path for either code in RatingScope's intake until this content is built.

Records to review: Records documenting rectovaginal or urethrovaginal fistula findings, if applicable.

DC 7629's own Note requires the diagnosis of endometriosis to be substantiated by laparoscopy before any tier of this code can be evaluated.

• RatingScope checks this laparoscopy-confirmation requirement first, before the pain/bleeding/lesion tier itself.
• A pending rule (RIN 2900-AS39) is fully researched from its own full NPRM text (not the tracked abstract) and confirmed note-only -- the 50 percent tier's own criterion text, including its laparoscopy dependency, is unchanged and VA states this will not change. Unified Agenda projects Final Action for August 2026.

Records to review: Laparoscopy records substantiating the endometriosis diagnosis.

Malignant neoplasms of the gynecological system (DC 7627) and the breast (DC 7630) both rate 100 percent while active, in treatment, or within six months of treatment cessation. After that, a mandatory VA examination determines the residual rating -- but the regulation names no specific destination code.

• This is the same time-limited-then-mandatory-dispatch shape as Thyroid and Parathyroid's DC 7900/7903, reused rather than reinvented.
• DC 7627 and DC 7630 are independently tracked -- a veteran with both a gynecological and a breast malignancy history has two separate six-month clocks, not one shared clock.

Records to review: Oncology treatment records establishing active status or the treatment cessation date.

This hub (38 CFR 4.116, DC 7610-7632) and the Genitourinary hub (38 CFR 4.115a/4.115b, DC 7500-7545) do not overlap.

• Confirmed by direct inspection of the Genitourinary hub's own education content (zero DC 76xx codes present) and its body-region registry entry (explicitly scoped to DC 7500-7545) -- this boundary was verified, not assumed, per this build's work order.
• If genitourinary symptoms are documented alongside a DC 7621 pelvic organ prolapse finding, review them separately under the Genitourinary hub's own diagnostic codes for the combination DC 7621 itself requires -- see the dedicated DC 7621 disclosure.

Records to review: Records documenting the specific organ system(s) affected.